Targeting the FOXM1/BUB1B signaling network in multiple myeloma: mechanistic insights and therapeutic potential.
1/5 보강
Multiple myeloma (MM) is a plasma cell cancer characterized by genomic instability and drug resistance.
APA
Yasin D, Sami N, et al. (2026). Targeting the FOXM1/BUB1B signaling network in multiple myeloma: mechanistic insights and therapeutic potential.. Leukemia & lymphoma, 67(5), 959-988. https://doi.org/10.1080/10428194.2025.2612628
MLA
Yasin D, et al.. "Targeting the FOXM1/BUB1B signaling network in multiple myeloma: mechanistic insights and therapeutic potential.." Leukemia & lymphoma, vol. 67, no. 5, 2026, pp. 959-988.
PMID
41578708 ↗
Abstract 한글 요약
Multiple myeloma (MM) is a plasma cell cancer characterized by genomic instability and drug resistance. The FOXM1 transcription factor and the BUB1B kinase are pivotal drivers of this malignancy. FOXM1 promotes cell cycle progression and is upregulated by oncogenic pathways like mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K)/AKT, correlating with aggressive disease. BUB1B ensures proper chromosome segregation, and its dysregulation fuels genomic instability. Critically, FOXM1 transcriptionally regulates BUB1B, forming an oncogenic axis that enhances proliferation, drug resistance, and survival. This FOXM1-BUB1B pathway is a promising therapeutic target, with inhibitors under preclinical investigation. Future research must validate its clinical relevance, explore combination therapies, and assess its potential as a biomarker to overcome challenges like toxicity and resistance.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Forkhead Box Protein M1
- Multiple Myeloma
- Signal Transduction
- Molecular Targeted Therapy
- Protein Serine-Threonine Kinases
- Cell Cycle Proteins
- Gene Expression Regulation
- Neoplastic
- Animals
- Antineoplastic Agents
- Drug Resistance
- Neoplasm
- Protein Kinase Inhibitors
- BUB1B
- FoxM1
- Multiple myeloma
- biomarkers
- cell cycle
- drug resistance
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.